NCI Technology Opportunities Webinar: GPC1 as a New Therapeutic Target in Pancreatic Cancer: Development of Antibodies and CAR-T

Register to attend a free NIH webinar. Attendees will learn about a new targeted immunotherapy pancreatic cancer treatment centered on the Glypican-1 (GPC1) cell surface heparan sulfate proteoglycan protein which is overexpressed in pancreatic cancer. The webinar will be presented by Dr. Mitchell Ho, Deputy Chief, NCI Laboratory of Molecular Biology.

Webinar overview: The inventors will discuss the development of their novel Chimeric Antigen Receptors (CARs) specific for GPC1 that include short Immunoglobulin subclass 4 (IgG4) hinge sequences between the extracellular antigen recognition domain and the transmembrane domain. Hinge changes in CAR design can achieve the threshold of antigen density required for optimal CAR-T cell activity. Specifically, the optimized GPC1-IgG4 hinge CARs show rapid and complete tumor regression in mouse models.